Epidermal growth factor antagonizes vasopressin in vivo and in vitro

Paddy A. Phillips, Sharon L. Grant, A. Fiona Davidson, John Risvanis, Jayne Stephenson, Christine B. Gow

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)


Since EGF causes diuresis through a renal action and may antagonize the hydroosmotic effect of AVP in vitro we investigated the antagonistic action of EGF with AVP in vivo and the mechanism of the antagonism in vitro. Conscious ewes received i.m. injections of a selective AVP V2-receptor agonist (1-desamino, D-Arg8 vasopressin acetate, DDAVP) every 12 hours for days 5 to 16. All ewes received an i.v. isotonic saline infusion (100 ml/day) for days 1 to 8 and days 13 to 16, and i.v. EGF in 100 ml saline/day at doses of 0 (N = 8) or 10 (N = 8) μg/hr for days 9 to 12. DDAVP reduced both urine volume and water intake, and increased urine osmolality. In contrast, simultaneous infusion of EGF reversed the DDAVP-induced responses, resulting in a transient negative fluid balance, kaliuresis and a transient natriuresis (all P < 0.05). When EGF treatment ceased, the effects of DDAVP treatment alone gradually became apparent. From the in vitro studies, the AVP-related peptides displaced specific AVP V1- and V2-receptor antagonist radioligands from rat renal inner medullary membranes, whereas EGF had no effect. However, EGF antagonized AVP V2-stimulated cAMP production in a dose-dependent way (IC50 = 2 x 10-7M). Therefore, the diuretic effect of EGF is not via direct antagonism of the antidiuretic AVP V2-receptor but seems mediated by inhibition of the antidiuretic AVP V2-receptor second messenger system.

Original languageEnglish
Pages (from-to)1028-1036
Number of pages9
JournalKidney International
Issue number4
Publication statusPublished - Apr 1994
Externally publishedYes


Dive into the research topics of 'Epidermal growth factor antagonizes vasopressin in vivo and in vitro'. Together they form a unique fingerprint.

Cite this